Syngene International closes deal with Strand Life Sciences to Purchase Systems Biology and Pharma Services Practice

India Infoline News Service | Mumbai | September 22, 2016, 11:38 IST

Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology andpre-emptive target validation services, all of which require strong bioinformatics capabilities.

Syngene
Syngene International Ltd., Asia’s leading Contract Research Organization, and Strand Life Sciences, announced that they have completed a deal through which Syngene has purchased assets of Strand LifeSciences related to systems biology, Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team. Financial details of the deal were notdisclosed.

Commenting on this development, Jonathan Hunt, Chief Executive Officer,Syngene International said, “Given the vast volumes of genetic material sequence data that is being generated globally, there is an increasing focus on biological information management and data analytics in drug discovery and development.

Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology andpre-emptive target validation services, all of which require strong bioinformatics capabilities. We believe Strand’s bioinformatics platforms not only complement ourexisting integrated service platforms but will also meet our customers growing needsfor bioinformatics and data analytic support.

Chairman and Managing Director of Strand Life Sciences, Dr. Vijay Chandru, added “Strand is glad that the deal with Syngene gives it access to technologies from Strandto form part of its integrated discovery service offerings. This transaction is also a keystep for Strand to focus its energies on personalized medicine through clinical applications of all its genomics technologies.”

Bioinformatics is a rapidly emerging area that promises tremendous growth potential. Companies involved in pharmaceutical, cosmetics, FMCG and agro-biotech R&D have strong focus on genomics, and need sound bioinformatics applications and platforms for developing better therapeutics and products. According to Transparency Market Research, the global bioinformatics market was estimated at $2.3 billion in 2012 and is forecasted to reach a market size of $9.1 billion in 2018, at a CAGR of25.4%.

This deal gives Syngene access to Strand’s patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver (both rat and human) using information from laboratorybased experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis, management and visualization tools for next-generation sequencing data.
 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.